• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

1987年至1995年奥地利甲状腺功能亢进症的发病率,这是在1990年盐加碘量增加之前和之后的情况。

The incidence of hyperthyroidism in Austria from 1987 to 1995 before and after an increase in salt iodization in 1990.

作者信息

Mostbeck A, Galvan G, Bauer P, Eber O, Atefie K, Dam K, Feichtinger H, Fritzsche H, Haydl H, Köhn H, König B, Koriska K, Kroiss A, Lind P, Markt B, Maschek W, Pesl H, Ramschak-Schwarzer S, Riccabona G, Stockhammer M, Zechmann W

机构信息

L. Boltzmann Institut für Nuklearmedizin, Wilhelminenspital, Vienna, Austria.

出版信息

Eur J Nucl Med. 1998 Apr;25(4):367-74. doi: 10.1007/s002590050234.

DOI:10.1007/s002590050234
PMID:9553166
Abstract

Between 1963 and 1990, Austria had iodized salt prophylaxis of endemic goitre with 10 mg KI (7.5 mg I) per kg. This was obviously insufficient, as urinary iodine excretion ranged from 42 to 78 microg I per g of creatinine and goitre in adults remained in the endemic range of 15%-30%. Therefore salt iodization was doubled in 1990. The aim of this study was to assess the annual incidence of different types of hyperthyroidism (HT) before and after this increase in salt iodization. The incidence of HT was recorded in 14 nuclear medicine centres from 1987 to 1995. In five additional centres data were available from 1992 onwards. Data prior to 1992 were documented retrospectively, while those after 1992 were recorded prospectively. The 14 centres drew patients from an area with a population of approximately 4.23 million while all 19 institutes were estimated to cover an area with a population of 5.4 million (the total population of Austria is 7.86 million). A total of 414232 persons were examined for the first time in the participating centres. HT and the type of HT were defined by clinical examination, serum TSH, thyroid hormone levels in blood, ultrasonography, scintigraphy and serum autoantibody titres. HT was classified into immunogenic HT (Graves' or Basedow's disease, GD) and HT with intrinsic thyroid autonomy (uni-, multinodular or disseminated Plummers' disease, PD). HT was also divided into overt (o) or subclinical (sc) disease. The following data were calculated: annual incidence per 100000 and the relative risk (RR) for HT with 95% confidence intervals (CI). In addition, linear trends were calculated for each type of HT by means of logistic regressions. In the 19 centres a total of 47834 patients with HT were registered from 1987 to 1995. PD accounted for 75% of all cases of HT and GD for 19%, while other types of HT were present in 6%. From 1987 to 1989 (time period T0), the annual incidence of oPD was 30.5 (95% CI 29.6-31.5) per 100000. The RR compared to the baseline period T0 was highest in 1992 (1.37; 1.3-1.45) and decreased to 1.17 (1.1-1.24) in 1995. The annual incidence of scPD in T0 was 27.4 (26.5-28.3) per 100000. The RR was highest in 1991 (1.64; 1.56-1.73) and was 1.60 (1. 51-1.69) in 1995. In oPD and scPD a higher RR was observed in persons older than 50 years of age, particularly in men. The incidence of oGD in T0 was 10.4 (9.8-10.9) per 100000; the maximum RR increased to 2.19 (2.01-2.38) in 1993 and decreased to 1.95 (1.78-2.13) in 1995. The incidence of scGD was 1.9 (1.6-2.1) in T0. The maximum RR was observed in 1994 (2.47; 2.04-3.0) and it was still 2.26 (1.85-2.77) in 1995. The increased incidence of oGD and scGD was evenly distributed in all ages and both sexes. The time course of different types of HT following the increase in salt iodization could be divided into two phases: an increase in the incidences of HT with peaks after 1-4 years and a subsequent decrease, the only exception being scGD. The effect was more pronounced in GD than in PD. PD showed an age and gender dependency over time, while GD did not.

摘要

1963年至1990年间,奥地利采用每千克加10毫克碘化钾(7.5毫克碘)的方式对地方性甲状腺肿进行碘盐预防。这显然是不够的,因为尿碘排泄量为每克肌酐42至78微克碘,成人甲状腺肿患病率仍处于15% - 30%的地方性流行范围。因此,1990年盐加碘量增加了一倍。本研究的目的是评估盐加碘量增加前后不同类型甲状腺功能亢进症(HT)的年发病率。1987年至1995年期间,在14个核医学中心记录了HT的发病率。另外5个中心从1992年起有相关数据。1992年以前的数据是回顾性记录的,而1992年以后的数据是前瞻性记录的。14个中心的患者来自一个约有423万人口的地区,而所有19个机构估计覆盖一个有540万人口的地区(奥地利总人口为786万)。参与中心共对414232人进行了首次检查。HT及其类型通过临床检查、血清促甲状腺激素、血液中的甲状腺激素水平、超声检查、闪烁扫描和血清自身抗体滴度来定义。HT分为免疫性HT(格雷夫斯病或巴塞多氏病,GD)和具有甲状腺自身自主性的HT(单结节、多结节或弥漫性普卢默病,PD)。HT也分为显性(o)或亚临床(sc)疾病。计算了以下数据:每10万人的年发病率以及HT的相对风险(RR)和95%置信区间(CI)。此外,通过逻辑回归计算了每种类型HT的线性趋势。1987年至1995年期间,19个中心共登记了47834例HT患者。PD占所有HT病例的75%,GD占19%,其他类型的HT占6%。1987年至1989年(时间段T0),oPD的年发病率为每10万人30.5(95%CI 29.6 - 31.5)。与基线期T0相比,RR在1992年最高(1.37;1.3 - 1.45),1995年降至1.17(1.1 - 1.24)。T0期scPD的年发病率为每10万人27.4(26.5 - 28.3)。RR在1991年最高(1.64;1.56 - 1.73),1995年为1.60(1.51 - 1.69)。在oPD和scPD中,50岁以上人群,尤其是男性,RR更高。T0期oGD的年发病率为每10万人10.4(9.8 - 10.9);最大RR在1993年升至2.19(2.01 - 2.38),1995年降至1.95(1.78 - 2.13)。T0期scGD的发病率为1.9(1.6 - 2.1)。最大RR在1994年观察到(2.47;2.04 - 3.0),1995年仍为2.26(1.85 - 2.77)。oGD和scGD发病率的增加在所有年龄和性别中分布均匀。盐加碘量增加后不同类型HT的时间进程可分为两个阶段:HT发病率在1 - 4年后达到峰值然后下降,唯一的例外是scGD。GD的影响比PD更明显。随着时间的推移,PD表现出年龄和性别依赖性,而GD则没有。

相似文献

1
The incidence of hyperthyroidism in Austria from 1987 to 1995 before and after an increase in salt iodization in 1990.1987年至1995年奥地利甲状腺功能亢进症的发病率,这是在1990年盐加碘量增加之前和之后的情况。
Eur J Nucl Med. 1998 Apr;25(4):367-74. doi: 10.1007/s002590050234.
2
[Iodine supply and struma in Austria].[奥地利的碘供应与甲状腺肿]
Acta Med Austriaca. 1993;20(1-2):3-5.
3
Endemic goitre in Finland and changes during 30 years of iodine prophylaxis.芬兰的地方性甲状腺肿以及碘预防30年间的变化
Endocrinol Exp. 1986 Mar;20(1):35-47.
4
[Prevalence of goiter and iodine deficiency in Saxony is less than previously assumed. A study 6 years after discontinuation of general iodization of table salt].[萨克森州甲状腺肿和碘缺乏症的患病率低于先前的假设。食盐全面加碘停止6年后的一项研究]
Med Klin (Munich). 2001 Jan 15;96(1):1-8. doi: 10.1007/pl00002147.
5
Epidemiological survey on the relationship between different iodine intakes and the prevalence of hyperthyroidism.不同碘摄入量与甲状腺功能亢进症患病率之间关系的流行病学调查。
Eur J Endocrinol. 2002 May;146(5):613-8. doi: 10.1530/eje.0.1460613.
6
Hyperthyroidism Prevalence in China After Universal Salt Iodization.中国普及食盐碘化后甲状腺功能亢进症的患病率。
Front Endocrinol (Lausanne). 2021 May 28;12:651534. doi: 10.3389/fendo.2021.651534. eCollection 2021.
7
[Should the iodination of table salt be increased in Austria?].奥地利是否应增加食盐加碘量?
Wien Med Wochenschr. 1985 Feb 15;135(3):71-5.
8
[Iodine deficiency in childhood despite prevention. Current data from the Vienna area].
Wien Klin Wochenschr. 1989 Apr 28;101(9):326-9.
9
Goiter prevalence, urinary iodine excretion, thyroid function and anti-thyroid function and anti-thyroid antibodies after 12 years of salt iodization in Shahriar, Iran.伊朗沙赫里亚尔地区实行食盐碘化12年后的甲状腺肿患病率、尿碘排泄量、甲状腺功能及抗甲状腺功能和抗甲状腺抗体情况
Int J Vitam Nutr Res. 2002 Oct;72(5):291-5. doi: 10.1024/0300-9831.72.5.291.
10
[Surgical therapy of functional autonomy--a retrospective study of the effect of the preventive use of iodized salt in Austria].[功能性自主的手术治疗——奥地利预防性使用碘盐效果的回顾性研究]
Acta Med Austriaca. 1990;17 Suppl 1:79-81.

引用本文的文献

1
Investigating serum iodine nutritional levels and their correlation with thyroid function in adult patients with Graves' hyperthyroidism at different treatment stages.调查不同治疗阶段Graves病成年甲亢患者的血清碘营养水平及其与甲状腺功能的相关性。
Front Endocrinol (Lausanne). 2025 Aug 27;16:1628670. doi: 10.3389/fendo.2025.1628670. eCollection 2025.
2
The Danish investigation on iodine intake and thyroid disease (DanThyr): history and implications.丹麦碘摄入量与甲状腺疾病研究(DanThyr):历史与意义。
Eur Thyroid J. 2024 May 20;13(3). doi: 10.1530/ETJ-23-0230. Print 2024 Jun 1.
3
Effect of iodine nutritional status on the recurrence of hyperthyroidism and antithyroid drug efficacy in adult patients with Graves' disease: a systemic review.
碘营养状况对成人格雷夫斯病患者甲亢复发和抗甲状腺药物疗效的影响:系统评价。
Front Endocrinol (Lausanne). 2023 Oct 11;14:1234918. doi: 10.3389/fendo.2023.1234918. eCollection 2023.
4
Hyperthyroidism incidence in a large population-based study in northeastern Italy.意大利东北部一项基于大规模人群研究中的甲状腺功能亢进发病率。
Endocr Connect. 2023 Nov 14;12(12). doi: 10.1530/EC-23-0292. Print 2023 Dec 1.
5
Register-based information on thyroid diseases in Europe: lessons and results from the EUthyroid collaboration.欧洲基于登记的甲状腺疾病信息:欧盟甲状腺合作项目的经验与成果
Endocr Connect. 2022 Mar 10;11(3):e210525. doi: 10.1530/EC-21-0525.
6
Real-World Data for Lenvatinib in Radioiodine-Refractory Differentiated Thyroid Cancer (RELEVANT): A Retrospective Multicentric Analysis of Clinical Practice in Austria.仑伐替尼用于放射性碘难治性分化型甲状腺癌的真实世界数据(RELEVANT):奥地利临床实践的回顾性多中心分析
Int J Endocrinol. 2020 Nov 28;2020:8834148. doi: 10.1155/2020/8834148. eCollection 2020.
7
Graves' disease.格雷夫斯病。
Nat Rev Dis Primers. 2020 Jul 2;6(1):52. doi: 10.1038/s41572-020-0184-y.
8
Incidence of thyroid disorders in the second decade of adequate iodine supply in Slovenia.斯洛文尼亚充足碘供应的第二个十年甲状腺疾病的发病率。
Wien Klin Wochenschr. 2021 Mar;133(5-6):182-187. doi: 10.1007/s00508-020-01662-5. Epub 2020 May 6.
9
Iodine Deficiency, Still a Global Problem?碘缺乏,仍是一个全球性问题?
Curr Health Sci J. 2017 Apr-Jun;43(2):103-111. doi: 10.12865/CHSJ.43.02.01. Epub 2017 Jun 29.
10
3rd Guideline for Perioperative Cardiovascular Evaluation of the Brazilian Society of Cardiology.巴西心脏病学会围手术期心血管评估第3版指南。
Arq Bras Cardiol. 2017 Jan-Feb;109(3 Supl 1):1-104. doi: 10.5935/abc.20170140.